Golimumab
Based on 1 Customer Validation
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.81%
- CAS 番号: 476181-74-5
- 分子量:146.94 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Caspase アイソフォーム固有の製品をすべて表示
More
生物活性
Human IgG1 kappa
Human
|
IL-1 |
IL-6 |
CD40 |
Golimumab (CNTO-148) (0.1-10 μg /mL; 24-72 hours; transmembrane TNFα–transfected Jurkat cells) induces reductions in the viability of transmembrane TNFα–expressing cells[1].
Golimumab (CNTO-148) (10 μg /mL; 48 hours; transmembrane TNFα–transfected Jurkat cells) induces apoptosis, increase the levels of active caspase-3 and induces apoptotic DNA fragmentation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Transmembrane TNFα–transfected Jurkat cells
-
Concentration:0.1, 1 and 10 μg/mL
-
Incubation Time:24, 48 and 72 hours
-
Result:Reduced cell viability in a dose- and time-dependent manner.
-
Cell Line:Transmembrane TNFα–transfected Jurkat cells
-
Concentration:10 μg /mL
-
Incubation Time:48 hours
-
Result:Had the percentage of apoptotic cells for 30.29%.
-
Cell Line:Transmembrane TNFα–transfected Jurkat cells
-
Concentration:10 μg /mL
-
Incubation Time:48 hours
-
Result:Increased the levels of active caspase-3 and induces apoptotic DNA fragmentation.
Golimumab (CNTO-148) (1-10 mg/kg; i.p.;daily; for 4 weeks; Tg197 transgenic mouse model) relieves TNFα-induced arthritis in a mouse model of human[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss-albino healthy male mice[2]
-
Dosage:24 mg/kg
-
Administration:Subcutaneous injection; daily, for 7 days
-
Result:Reduced serum parameters like BUN, NGAL creatinine, cystatin C, and urinary parameters like KIM-1, NAG, albumin clusterin.
-
Animal Model:Swiss-albino healthy male mice[2]
-
Dosage:24 mg/kg
-
Administration:Subcutaneous injection; daily, for 7 days
-
Result:Inhibited oxidative stress, reduces MDA concentrations and increases the GSH and catalase levels.
-
Animal Model:Swiss-albino healthy male mice[2]
-
Dosage:24 mg/kg
-
Administration:Subcutaneous injection; daily, for 7 days
-
Result:Inhibitd cisplatin-induced inflammation, decreased TNF-α, including IL-6, IL-1β, MCP-1, ICAM-1, and TGF-β1 levels and increases IL-10 concentrations, reduced caspase 3 in cisplatin injected mice kidneys.
-
Animal Model:Tg197 transgenic mouse model[3]
-
Dosage:1 and 10 mg/kg
-
Administration:Intraperitoneal injection;for 4 weeks
-
Result:Reduced the arthritic index.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized TNF-alpha/TNFSF2 Protein, Human (HY-P7058) can bind Golimumab. The EC50 for this effect is 2.75 ng/mL. -
Flow cytometric analysis of 1.5X106 RAW264.7 cells treated with 1µg/mL LPS for 24h labeling Golimumab (HY-P99111, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃, Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control，cells without incubation with primary antibody were used as the unlabeled control (black).
化学情報
-
CAS 番号 476181-74-5
-
性状 Liquid
-
分子量 146.94 kDa
-
Color Colorless to light yellow
-
SMILES
[Golimumab]
-
別名
CNTO-148
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (266 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Ueda N, et, al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α. Inflamm Bowel Dis. 2013 May;19(6):1224-31. [Content Brief]
[2]. Pavitrakar V, et, al. Amelioration of Cisplatin-induced Renal Inflammation by Recombinant Human Golimumab in Mice. Curr Pharm Biotechnol. 2022;23(7):970-977. [Content Brief]
[3]. Shealy DJ, et, al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2010 Jul-Aug;2(4):428-39. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Golimumab 関連分類
HY-P99111 関連分類
Powered by Bioz